Cemsidomide with elranatamab for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Injuries & trauma clinical trials.
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or stopped responding to treatment.
- You have had 1 to 4 prior rounds of therapy, including at least one immunomodulatory drug.
- You are able to swallow pills and your stomach and intestines work normally.
- You have not had a stem cell transplant in the last 12 weeks or have active graft-versus-host disease.
- You have not been treated with a BCMA-directed therapy (like a type of immunotherapy) before.
- You do not have any serious active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.